STAT signaling in the pathogenesis and treatment of cancer

Molecular Medicine

Volumn 5, Issue 7, 1999, Pages 432-456

  Frank, David A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; PROTEIN TYROSINE KINASE; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN;

ACUTE LEUKEMIA; APOPTOSIS; BREAST CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CANCER RESEARCH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; ENZYME ACTIVITY; LYMPHOMA; MULTIPLE MYELOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0032772912     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03403538     Document Type: Review

References (245)

1. Levy DE, Kessler DS, Pine R, Reich N, Darnell JE Jr. (1988) Interferon-induced nuclear factors that bind a shared promoter correlate with positive and negative transcriptional control. Genes Dev. 2: 383-393.
2. Khan KD, Shuai K, Lindwall G, Maher SE, Darnell JE Jr, Bothwell AL. (1993) Induction of the Ly-6A/E gene by interferon alpha/beta and gamma requires a DNA element to which a tyrosine-phosphorylated 91-kDa protein binds. Proc. Natl. Acad. Sci. U.S.A. 90: 6806-6810.
3. Fu X-Y, Schindler C, Improta T, Aebersold R, Darnell JE Jr. (1992) The proteins of ISGF-3, the interferon α-induced transcriptional activator, define a gene family involved in signal transduction. Proc. Natl. Acad. Sci. U.S.A. 89: 7840-7843.
4. Shuai K, Schindler C, Prezioso VR, Darnell JE Jr. (1992) Activation of transcription by IFN-γ: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 258: 1808-1812.
5. Velazquez L, Fellous M, Stark G, Pellegrini S. (1992) A protein tyrosine kinase in the interferon α/β signaling pathway. Cell 70: 313-322.
6. Muller M, Briscoe J, Laxton C, et al. (1993) The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and gamma signal transduction. Nature 366: 129-135.
7. Walting D, Guschin D, Muller M. (1993) Complementation by the protein tyrosine kinase JAK-2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature 366: 166-170.
8. Silvennoinen O, Ihle JN, Schlessinger J, Levy DE. (1993) Interferon-induced nuclear signaling by Jak protein tyrosine kinases. Nature 366: 583-585.
9. 1yk2, an interferon-α-activated tyrosine kinase, is physically associated with an interferon-α receptor. J. Biol. Chem. 269: 3518-3522.
10. Heim MH, Kerr IM, Stark GR, Darnell JE Jr. (1995) Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway. Science 267: 1347-1349.
11. Stahl N, Farruggella TJ, Boulton TG, Zhong Z, Darnell JE Jr, Yancopoulos GD. (1995) Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 267: 1349-1353.
12. Shuai K, Stark GR, Kerr IM, Darnell JE Jr. (1993) A single phosphotyrosine residue of Stat91 required for gene activation by interferon-γ. Science 261: 1744-1746.
13. Shuai K, Horvath CM, Huang LHT, Qureshi SA, Cowburn D, Darnell JE Jr. (1994) Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 76: 821-828.
14. Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE Jr, Kuriyan J. (1998) Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 93: 827-839.
15. Bhattacharya S, Eckner R, Grossman S, et al. (1996) Cooperation of Stat2 and p300/CBP in signalling induced by interferon-α. Nature 383: 344-347.
16. Zhang JJ, Vinkemeier U, Gu W, Chakravarti D, Horvath CM, Darnell JE Jr. (1996) Two contact regions between Stat1 and CBP/p300 in Interferon γ signaling. Proc. Natl. Acad. Sci. U.S.A. 93: 15092-15096.
17. Horvai AE, Xu L, Korzus E, et al. (1997) Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300. Proc. Natl. Acad. Sci. U.S.A. 94: 1074-1079.
18. Kurokawa R, Kalafus D, Ogliastro M-H, et al. (1998) Differential use of CREB binding protein-coactivator complexes. Science 279: 700-703.
19. Korzus E, Torchia J, Rose DW, et al. (1998) Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 279: 703-707.
20. David M, Grimely PM, Finbloom DS. (1993) A nuclear tyrosine phosphatase downregulates interferon-induced gene expression. Mol. Cell. Biol. 13: 5715-5721.
21. Haque SJ, Flati V, Deb A, Williams BR. (1995) Roles of protein-tyrosine phosphatases in Stat1 alpha-mediated cell signaling. J. Biol. Chem. 270: 25709-25714.
22. Kim TK, Maniatis T. (1996) Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science 273: 1717-1719.
23. Haspel RL, Salditt-Georgieff M, Darnell JE Jr. (1996) The rapid inactivation of nuclear tyrosine phosphoryloted Stat1 depends upon a protein tyrosine phosphatase. EMBO J. 15: 6262-6268.
24. Yu CL, Burakoff SJ. (1997) Involvement of proteasomes in regulating Jak-STAT pathways upon interleukin-2 stimulation. J. Biol. Chem. 272: 14017-14020.
25. Matsumoto A, Masuhara M, Mitsui K, et al. (1997) CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 89: 3148-3154.
26. Starr R, Willson TA, Viney EM, et al. (1997) A family of cytokine-inducible inhibitors of signaling. Nature 387: 917-921.
27. Endo TA, Masuhara M, Yokouchi M, et al. (1997) A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387: 921-924.
28. Naka T, Narazaki M, Hirata M, et al. (1997) Structure and function of a new STAT-induced STAT inhibitor. Nature 387: 924-928.
29. Chung CD, Liao J, Liu B, et al. (1997) Specific inhibition of Stat3 signal transduction by PIAS3. Science 278: 1803-1805.
30. Liu B, Liao J, Rao X, et al. (1998) Inhibition of Stat1-mediated gene activation by PIAS1. Proc. Natl. Acad. Sci. U.S.A. 95: 10626-10631.
31. Beadling C, Guschin D, Witthuhn BA, et al. (1994) Activation of JAK kinases and STAT proteins by interleukin-2 and Interferon α, but not the T cell antigen receptor, in human T lymphocytes. EMBO J. 13: 5605-5615.
32. Nielsen M, Svejgaard A, Skov S, Odum N. (1994) Interleukin-2 induces tyrosine phosphorylation and nuclear translocation of stat3 in human T lymphocytes. Eur. J. Immunol. 24: 3082-3086.
33. Frank DA, Robertson M, Bonni A, Ritz J, Greenberg ME. (1995) IL-2 signaling involves the phosphorylation of novel Stat proteins. Proc. Natl. Acad. Sci. U.S.A. 92: 7779-7783.
34. Hou J, Schindler U, Henzel WJ, Wong SC, McKnight SL. (1995) Identification and purification of human Stat proteins activated in response to interleukin-2. Immunity 2: 321-329.
35. Wang KS, Ritz J, Frank DA. (1999) IL-2 induces STAT4 activation in primary NK cells and NK cell lines but not in T cells. J. Immunol. 162: 299-304.
36. Larner AC, David M, Feldman GM, et al. (1993) Tyrosine phosphorylation of DNA binding proteins by multiple cytokines. Science 261: 1730-1733.
37. Kotanides H, Reich NC. (1993) Requirement of tyrosine phosphorylation for rapid activation of a DNA binding factor by IL-4. Science 262: 1265-1267.
38. Schindler C, Kashleva H, Pernis A, Pine R, Rothman P. (1994) STF-IL-4: a novel IL-4-induced signal transducing factor. EMBO J. 13: 1350-1356.
39. Wegenka UM, Buschmann J, Lutticken C, Heinrich PC, Horn F. (1993) Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol. Cell. Biol. 13: 276-288.
40. Yuan J, Wegenka UM, Lutticken C, et al. (1994) The signalling pathways of interleukin-6 and gamma interferon converge by the activation of different transcription factors which bind to common responsive DNA elements. Mol. Cell. Biol. 14: 1657-1668.
41. Bacon CM, Petricoin EFI, Ortaldo JR, et al. (1995) Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 92: 7307-7311.
42. Wegenka UM, Lutticken C, Buschmann J, et al. (1994) The interleukin-6-activated acute-phase response factor is antigenically and functionally related to members of the signal transducer and activator of transcription (STAT) family. Mol. Cell. Biol. 14: 186-196.
43. Lowe C, Gillespie GA, Pike JW. (1995) Leukemia inhibitory factor as a mediator of JAK/STAT activation in murine osteoblasts. J. Bone Min. Res. 10: 1644-1650.
44. Symes AJ, Corpus L, Fink JS. (1995) Differences in nuclear signaling by leukemia inhibitory factor and interferon-gamma: the role of STAT proteins in regulating vasoactive intestinal peptide gene expression. J. Neurochem. 65: 1926-1933.
45. Boulton TG, Zhong Z, Wen Z, Darnell JE Jr, Stahl N, Yancopoulos GD. (1995) STAT3 activation by cytokines utilizing gp130 and related transducers involves a secondary modification requiring an H7-sensitive kinase. Proc. Natl. Acad. Sci. U.S.A. 92: 6915-6919.
46. Zhao Y, Nichols JE, Bulun SE, Mendelson CR, Simpson ER. (1995) Aromatase P450 gene expression in human adipose tissue. Role of a Jak/STAT pathway in regulation of the adipose-specific promoter. J. Biol. Chem. 270: 16449-16457.
47. Morella KK, Bruno E, Kumaki S, et al. (1995) Signal transduction by the receptors for thrombopoietin (c-mpl) and interleukin-3 in hematopoietic and nonhematopoietic cells. Blood 86: 557-571.
48. Pallard C, Gouilleux F, Benit L. et al. (1995) Thrombopoietin activates a STAT5-like factor in hematopoietic cells. EMBO J. 14: 2847-2856.
49. Sattler M, Durstin MA, Frank DA, et al. (1995) The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosinc kinases. Exp. Hematol. 23: 1040-1048.
50. Silvennoinen O, Schindler C, Schlessinger J, Levy DE. (1993) Ras-independent growth factor signaling by transcription factor tyrosine phosphorylation. Science 261: 1736-1739.
51. Novak U, Mui A, Miyajima A, Paradiso L. (1996) Formation of STAT5-containing DNA binding complexes in response to colony-stimulating factor-1 and platelet-derived growth factor. J. Biol. Chem. 271: 18350-18354.
52. Tweardy DJ, Wright TM, Ziegler SF, et al. (1995) Granulocyte colony-stimulating factor rapidly activates a distinct STAT-like protein in normal myeloid cells. Blood 86: 4408-4416.
53. Chakraborty A, White SM, Schaefer TS, Ball ED, Dyer KF, Tweardy DJ. (1996) Granulocyte colony-stimulating factor activation of Stat3α and Stat3β in immature normal and leukemic human myeloid cells. Blood 88: 2442-2448.
54. Argetsinger LS, Campbell GS, Yang X, et al. (1993) Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 74: 237-244.
55. Meyer DJ, Campbell GS, Cochran BH, et al. (1994) Growth hormone induces a DNA binding factor related to the interferon-stimulated 91-kDa transcription factor. J. Biol. Chem. 269: 4701-4704.
56. Symes A, Lewis S, Corpus L, Rajan P, Hyman SE, Fink JS. (1994) STAT proteins participate in the regulation of the vasoactive intestinal peptide gene by the ciliary neurotrophic factor family of cytokines. Mol. Endocrinol. 8: 1750-1763.
57. Gouilleux F, Pallard C, Dusanter-Fourt I, et al. (1995) Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity. EMBO J. 14: 2005-2013.
58. Gouilleux F, Wakao H, Mundt M, Groner B. (1994) Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J. 13: 4361-4369.
59. Rui H, Kirken RA, Farrar WL. (1994) Activation of receptor-associated tyrosine kinase JAK2 by prolactin. J. Biol Chem. 269: 5364-5368.
60. Bonni A, Frank DA, Schindler C, Greenberg ME. (1993) Characterization of a pathway for ciliary neurotrophic factor signaling to the nucleus. Science 262: 1575-1579.
61. Guo D, Dunbar JD, Yang CH, Pfeffer LM, Donner DB. (1998) Induction of Jak/STAT signaling by activation of the type 1 TNF receptor. J. Immunol. 160: 2742-2750.
62. Bhat GJ, Thekkumkara TJ, Thomas WG, Conrad KM, Baker KM. (1994) Angiotensin II stimulates sis-inducing factor-like DNA binding activity. Evidence that the ATIA receptor activates transcription factor-Stat91 and/or a related protein. J. Biol. Chem. 269: 31443-31449.
63. Marrero MB, Schieffer B, Paxton WG, et al. (1995) Direct stimulation of Jak/STAT pathway by the angiotensin II AT, receptor. Nature 375: 247-250.
64. Chaturvedi P, Reddy MV, Reddy EP. (1998) Src kinases and not JAKs activate STATs during IL-3 induced mycloid cell proliferation. Oncogene 16: 1749-1758.
65. Saharinen P, Ekman N, Sarvas K, Parker P, Alitalo K, Silvennoinen O. (1997) The Bmx tyrosine kinase induces activation of the Slat signaling pathway, which is specifically inhibited by protein kinase Cδ. Blood 90: 4341-4353.
66. Yamashita Y, Walanabe S, Miyazato A, et al. (1998) Tec and Jak2 cooperate to mediate cytokine-driven activation of c-fos transcription. Blood 91: 1496-1507.
67. Fu X, Zhang J. (1993) Transcription factor p91 interacts with the epidermal growth factor receptor and mediates activation of the c-fos gene promoter. Cell 74: 1135-1145.
68. Ruff-Jamison S, Chen K, Cohen S. (1993) Induction by EGF and interferon-γ of tyrosine phosphorylated DNA binding proteins in mouse liver nuclei. Science 261: 1733-1736.
69. Sadowski HB, Shuai K, Darnell JE Jr, Gilman MZ. (1993) A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science 261: 1739-1744.
70. Park OK, Schaeffer TS, Nathans D. (1996) In vitro activation of Stat3 by epidermal growth factor receptor kinase. Proc. Natl. Acad. Sci. U.S.A. 93: 13704-13708.
71. Leaman DW, Pisharody S, Flickinger TW, et al. (1996) Roles of JAKs in activation of STATs and stimulation of c-fos gene expression by epidermal growth factor. Mol Cel. Biol. 16: 369-375.
72. Chen J, Sadowski HB, Kohanski RA, Wang I.-H. (1997) Stat5 is a physiologic substrate of the insulin receptor. Proc. Natl. Acad. Sci. U.S.A. 94: 2295-2300.
73. Karras JG, Wang Z, Coniglio SJ, Frank DA, Rothstein TL. (1996) Antigen-receptor engagement in 8 cells induces nuclear expression of STAT5 and STAT6 proteins that bind and transactivate an IFN-gamma activation site. J. Immunol. 157: 39-47.
74. Frank DA, Mahajan S, Ritz J. (1998) Activation of T cells through CD2 leads to the delayed and prolonged activation of STAT1. Blood 92: 701a.
75. Simon AR, Rai U, Fanburg BL, Cochran BH. (1998) Activation of the JAK-STAT pathway by reactive oxygen species. Am. J. Physiol. 275: C1640-1652.
76. Sattler M, Winkler T, Verma S, et al. (1999) Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood 93: 2928-2935.
77. Wen Z, Zhong z, Darnell JE Jr. (1995) Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82: 241-250.
78. Zhang X, Blenis J, Li H-C, Schindler C, Chen-Kiang S. (1995) Requirement of serine phosphorylation for formation of Stat-promoter complexes. Science 267: 1990-1994.
79. Wen Z, Darnell JE Jr. (1997) Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucl. Acids Res. 25: 2062-2067.
80. Turkson J, Bowman T, Adnane J, et al. (1999) Requirement of Rac-1 mediated p38 and JNK signaling for Stat3 transcriptional activity induced by the Src oncoprotein. Mol. Cell. Biol. (in press).
81. Gollob JA, Schnipper CP, Murphy EA, Ritz J, Frank DA. (1999) The functional synergy between IL-12 and IL-2 involves p38 MAP kinase and is associated with the augmentation of STAT serine phosphorylation. J. Immunol. 162: 4472-4481.
82. Rajotte D, Sadowski HB, Haman A, et al. (1996) Contribution of both STAT and SRF/TCF to c-fos promoter activation by granulocyte-macrophage colony stimulating factor. Blood 88: 2906-2916.
83. Frank DA, Mahajan S, Ritz J. (1997) B lymphocytes from patients with chronic lymphocytic leukemia contain STAT1 and STAT3 constitulively phosphorylated on serine residues. J. Clin. Invest. 100: 3140-3148.
84. Ihle JN. (1996) STATs: signal transducers and activators of transcription. Cell 84: 331-334.
85. Ihle JN, Kerr IM. (1995) Jaks and stats in signaling by the cytokine receptor superfamily. Trends Genet. 11: 69-74.
86. Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Silvennoinen O. (1995) Signaling through hematopoietic cytokine receptors. Annu. Rev. Immunol. 13: 369-398.
87. Darnell JE Jr. (1997) STATs and gene regulation. Science 277: 1630-1635.
88. Darnell JE Jr, Kerr IM, Stark GR. (1994) Jak-STAT pathway and transcription activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1420.
89. Schindler C, Fu X-Y, Improta T, Acbersold R, Darnell JE Jr. (1992) Proteins of transcription Factor ISGF-3: one gene encodes the 91 and 84 kDa ISGF-3 proteins that are activated by interferon-α. Proc. Natl. Acad. Sci. U.S.A. 89: 7836-7839.
90. Schaefer TS, Sanders LK, Nathans D. (1995) Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3. Proc. Natl. Acad. Sci. U.S.A. 92: 9097-9101.
91. Mikita T, Campbell D, Wu P, Williamson K, Schindler U. (1996) Requirements for interleukin-4-induced gene expression and functional characterization of Stat6. Mol. Cell. Biol. 16: 5811-5820.
92. Delphin S, Stavenezer J. (1995) Characterization of an interleukin 4 (IL-4) responsive region in the immunoglobulin heavy chain germline epsilon promoter: regulation by NF-IL-4, a C/EBP family member and NF-kappa B/p50. J. Exp. Med. 181: 181-192.
93. Look DC, Pelletier MR, Tidwell RM, Roswit WT, Holtzman MJ. (1995) Stat1 depends on transcriptional synergy with Spl. J. Biol. Chem. 270: 30264-30267.
94. Stocklin E, Wissler M, Gouilleux F, Groner B. (1996) Functional interactions between Stat5 and the glucocorticoid receptor. Nature 383: 726-728.
95. Wagner BJ, Hayes TE, Hoban CJ, Cochran BH. (1990) The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter. EMBO J. 9: 4477-4484.
96. Zhong Z, Wen Z, Darnell Jr JE. (1994) Stat3: a STAT family member activated by tyrosine phosphorylation in response 10 epidermal growth factor and imerleukin-6. Science 264: 95-98.
97. Ruff-Jamison S, Chen K, Cohen S. (1995) Epidermal growth factor induces the tyrosine phosphorylation and nuclear translocation of Stat 5 in mouse liver. Proc. Natl. Acad. Sci. U.S.A. 92: 4215-4218.
98. Ruff-Jamison S, Zhong Z, Wen Z, Chen K, Darnell JE Jr, Cohen S. (1994) Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver. J. Biol. Chem. 269: 21933-21935.
99. Mui AL, Wakao H, Kinoshita T, Kitamura T, Miyajima A. (1996) Suppression of interleukin3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation. EMBO J. 15: 2425-2433.
100. Grandis JR, Drenning SD, Chakraborty A, et al. (1998) Requirement of Stat3 but not Stal1 activation for epidermal growth factor-mediated cell growth in vitro. J. Clin. Invest. 102: 1385-1392.
101. Marra F, Choudhury GG, Abboud HE. (1996) Interferon-γ-mediated activation of STAT1α regulates growth factor-induced mitogenesis. J. Clin. Invest. 98: 1218-1230.
102. WAF1/CIP1 mediated by STAT1. Science 272: 719-722.
103. Wakao H, Gouilleux F, Groner B. (1994) Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J. 13: 2182-2191.
104. Coffman RL, Lebman DA, Rothman P. (1993) Mechanism and regulation of immunoglobulin isotype switching. Adv. Immunol. 54: 229.
105. Rothman P, Li SC, Gorham B, Glimcher L, Alt F, Boothby M. (1991) Identification of a conserved lipopolysaccharide-plus-interleukin-4-responsiveelement located at the promoter of germ line epsilon transcripts. Mol. Cell. Biol. 11: 5551-5561.
106. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. (1996) Stat6 is required for mediating responses to IL-4 and for the development of Th2 cells. Immunity 4: 313-319.
107. Miller DM, Rahill BM, Boss JM, et al. (1998) Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J. Exp. Med. 187: 675-683.
108. Kaplan MH, Sun Y-L, Hocy T, Grusby MJ. (1996) Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 382: 174-177.
109. Thierfelder WE, van Deursen JM, Yamamoto K, et al. (1996) Requirement for Stat4 in interleukin-12-mediated response of natural killer and T cells. Nature 382: 171-174.
110. Bonni A, Sun Y, Nadal-Vicens M, et al. (1997) Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science 278: 477-483.
111. Hauser PJ, Agrawal D, Hackney J, Pledger WJ. (1998) STAT3 activation accompanies keratinocyte differentiation. Cell Growth Differ. 9: 847-855.
112. Shimozaki K, Nakajima K, Hirano T, Nagata S. (1997) Involvement of STAT3 in granulocyte colony-stimulating factor-induced differentiation of myeloid cells. J. Biol. Chem. 272: 25184-25189.
113. Boccaccio C, Ando M, Tamagnone L, et al. (1998) Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391: 285-288.
114. Kumar A, Commane M, Flickinger TW, Horvath CM, Stark GR. (1997) Defective TNF-α-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 278: 1630-1632.
115. Xu X, Fu X-Y, Plate J, Chong AS-F. (1998) IFN-γ induces cell growth inhibition by fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res. 58: 2832-2837.
116. Skov S, Nielsen M, Bregenholt S, Odum N, Claesson MH. (1998) Activation of Stat-3 is involved in the induction of apoptosis after ligation of major histocompatibility complex class I molecules on human Jurkat T cells. Blood 91: 3566-3573.
117. Frank DA, Mahajan S, Yuan H. (1999) The chemoprotectant butyrate downregulates IL-6 induced signaling events in colorectal carcinoma cells. Proc. Amer. Assoc. Cancer Res. 40: 318.
118. Fujio Y, Kunisada K, Hirota H, Yamauchi-Takihara K, Kishimoto T. (1997) Signals through gp130 upregulate bcl-x gene expression via STAT1-binding cis-element in cardiac myocytes. J. Clin. Invest. 99: 2898-2905.
119. Binari R, Perrimon N. (1994) Stripe-specific regulation of pair-rule genes by hopscotch, a putative Jak family tyrosine kinase in Drosophila. Genes Dev. 8: 300-312.
120. Hou XS, Melnick MB, Perrimon N. (1996) marelle acts downstream of the Drosophila HOP/JAK kinase and encodes a protein similar to mammalian STATs. Cell 84: 411-419.
121. Yan R, Small S, Desplan C, Dearolf CR, Darnell JE Jr. (1996) Identification of a Stat gene that functions in Drosaphila development. Cell 84: 421-430.
122. Tum-1 Jak kinase causes leukemia-like hematopoietic defects. EMBO J. 14: 1412-1420.
123. Harrison DA, Binari R, Nahrenini TS, Gilman M, Perrimon N. (1995) Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. EMBO J. 14: 2857-2865.
124. Gouilleux-Gruart V, Gouilleux F, Desaint C, et al. (1996) STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 87: 1692-1697.
125. Weber-Nordt RM, Egen C, Wehinger J, et al. (1996) Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88: 809-816.
126. Xia Z, Baer MR, Block AW, Baumann H, Wetzler M. (1998) Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts. Cancer Res. 58: 3173-3180.
127. Nowell PC, Hungerford DA. (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132: 1497-1499.
128. Rowley JD. (1973) A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa banding. Nature 243: 290-291.
129. Konopka JB, Watanabe SM, Witte ON. (1984) An alteration of the human c-abl protein in K562 unmasks associated tyrosine kinase activity. Cell 37: 1035-1042.
130. Shtivelman E, Lifshitz B, Gale RP, Canaani E. (1985) Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 315: 550-554.
131. Gishizky ML, Witte ON. (1992) Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science 256: 836-839.
132. Daley GQ, Van Etten RA, Baltimore D. (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247: 824-830.
133. Daley GQ, Baltimore D. (1988) Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl. Acad. Sci. U.S.A. 85: 9312-9316.
134. Carlesso N, Frank DA, Griffin JD. (1996) Tyrosyl phosphorylation and DNA-binding activity of STAT proteins in hematopoietic cell lines transformed by Bcr/Abl. J. Exp. Med 183: 811-820.
135. Frank DA, Varticovski L. (1996) BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia 10: 1724-1730.
136. RCR/ABL induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 271: 31704-31710.
137. Shuai K, Halpern J, ten Hoevc J, Rao X, Sawyers CL. (1996) Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13: 247-254.
138. Chai SK, Nichols GL, Rothman P. (1997) Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J. Immunol. 159: 4720-4728.
139. Kurzrock R, Gutterman J, Talpaz M. (1988) The molecular genetics of Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 319: 990-998.
140. Nieborowska-Skorska M, Wasik MA, Salomoni P, Kitamura T, Calabretta B, Skorski T. (1998) STAT5 activation by Bcr/Abl is dependent on its intact SH3 and SH2 domains and is required for leukemogenesis. Blood 92: 91a.
141. Rozman C, Montserrat E. (1995) Chronic lymphocytic leukernia. New Engl. J. Med. 333: 1052-1057.
142. Lin J-X. (1995) The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 2: 331-339.
143. Tanner JE, Tosato G. (1992) Regulation of B-cell growth and immunoglobulin gene transcription by interleukin-6. Blood 79: 452-459.
144. Nielsen M, Kaltoft K, Nordahl M, et al. (1997) Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrpbostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc. Natl. Acad. Sci. U.S.A. 94: 6764-6769.
145. Zhang Q, Nowak I, Vonderheid EC, et al. (1996) Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc. Natl. Acad. Sci. U.S.A. 93: 9148-9153.
146. Migone T-S, Lin J-X, Cereseto A, et al. (1995) Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 269: 79-81.
147. Takemoto S, Mulloy JC, Cereseto A, et al. (1997) Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc. Natl. Acad. Sci. U.S.A. 94: 13897-13902.
148. Xu X, Kang SH, Heidenreich O, Okerholm M, O'Shea JJ, Nerenberg MI. (1995) Constitutive activation of different Jak kinases in human T cell leukemia virus type 1 (HTLV-I) tax protein or virus-transformed cells, J. Clin. Invest. 96: 1548-1555.
149. Smith D, Buckle GJ, Hafler DA, Frank DA, Hollsberg P. (1999) HTLV-I infected T cells evade the anti-proliferative action of IFN-beta. Virology 257: 314-321.
150. Kawano M, Hirano T, Matsuda T, et al. (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83-85.
151. Andersen KC, Jones RM, Morimoto C, Leavitt P, Barut BA. (1989) Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 73: 1915-1924.
152. Levy Y, Tsapis A, Brouct JC. (1991) Interleukin-6 antisense oligonucleotides inhibit the growth of human mycloma cell lines. J. Clin. Invest. 88: 696-699.
153. Klein B, Zhang XG, Yang LZ, Bataille R. (1995) Interleukin-6 in human multiple myeloma. Blood 85: 863-874.
154. Hilbert DM, Kopf M, Mock BA, Kohler G, Rudikoff S. (1995) Interleukin 6 is essential for in vivo development of B lineage neoplasms. J. Exp. Med. 182: 243-248.
155. Hibert DM, Migone T-S, Kopf M, Leonard WJ, Rudikoff S. (1996) Distinct tumorigenic potential of abl and raf in B cell neoplasia: abl activates the IL-6 signaling pathway. Immunity 5: 81-89.
156. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115.
157. Barut B, Chauhan D, Uchiyama H, Anderson KC. (1993) Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro. J. Clin. Invest. 92: 2346-2352.
158. Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. (1995) Serum interleukin-6 levels correlate with prognosis in diffuse large cell lymphoma. J. Clin. Oncol. 13: 575-582.
159. Pallard C, Gouilleux F, Charon M, Groner B, Gisselbrecht S, Dusanter-Fourt I. (1995) Interleukin-3, crythropoictin, and prolactin activate a STAT5-like factor in lymphoid cells. J. Biol. Chem. 270: 15942-15945.
160. Watson CJ, Miller WR. (1995) Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br. J. Cancer 71: 840-844.
161. Garcia R, Yu C-L, Hudnall A, et al. (1997) Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. 8: 1267-1276.
162. Sartor CI, Dziubinski ML, Yu CL, Jove R, Ethier SP. (1997) Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. Cancer Res. 57: 978-987.
163. Manni A, Trout D, Verderame MF, Beaston-Wimmer PR. (1999) Ornithine decarboxylase (ODC) overexpression activates Src and STAT signaling in MCF-10A human breast epithelial cells. Proc. Am. Assoc. Cancer Res. 40: 99.
164. Endo S, Zeng Q, He Y, et al. (1999) Increased Stat3 activation in head and neck tumors in vivo. Proc. Am. Assoc. Cancer Res. 40: 336.
165. Rubin Grandis J, Chakraborty A, Mclhem MF, Zeng Q, Tweardy DJ. (1997) Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogens 15: 409-416.
166. Zhou MY, Zeng Q, Drenning SD, Rubin Grandis J. (1999) Differential activation of STAT5 iso-forms and growth control in head and neck cancer. Proc. Am. Assoc. Cancer Res. 40: 335.
167. Reddy MVR, Chaturvedi P, Reddy EP. (1999) Src kinase mediated activation of STAT-3 plays an essential role in the proliferation and oncogenicity of human breast, prostate and ovarian carcinomas. Proc. Am. Assoc. Cancer Res. 40: 376.
168. Kirkwood JM, Farkas DL, Chakraborty A, et al. (1999) Systemic interferon-α (IFN-α) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol. Med. 5: 11-20.
169. Shirota K, LeDuy L, Yuan SY, Jothy S. (1990) Interleukin-6 and its receptor are expressed in human intestinal epithelial cells. Virchows Arch B Cell Pathol 58: 303-308.
170. Burkitt DP. (1971) Epidemiology of cancer of the colon and rectum. Cancer 28: 3-13.
171. Howe GR, Benito E, Castelleto R, et al. (1992) Dietary intake of fiber and decreased risk of cancers of the colon and rectum: evidence from the combined analysis of 13 case-control studies. J. Natl Cancer Inst. 84: 1887-1896.
172. Reddy BS, Hedges AR, Laakso K, Wynder EL. (1978) Metabolic epidemiology of large bowel cancer: fecal bulk and constituents of high-risk North American and low-risk Finnish population. Cancer 42: 2832-2838.
173. Trock B, Lanza E, Greenwald P. (1990) Dietary fiber, vegetables, and colon cancer: critical review and meta-analyses of the cpidemiologic evidence. J. Natl. Cancer Inst. 82: 650-661.
174. Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, Yoshida O. (1995) Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res. 55: 590-596.
175. Borsellino N, Belldegrun A, Bonavida B. (1995) Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 55: 4633-4639.
176. Kowalczyk J, Sandberg AA. (1983) A possible subgroup of ALL with 9p-. Cancer Genet. Cytogenet. 9: 383-388.
177. Chilcote RR, Brown E, Rowley JD. (1985) Lymphoblastic leukemia with features associated with abnormalities of the short arm of chromosome 9. N. Engl. J. Med. 313: 286-289.
178. Pollack C, Hagemeijer A. (1987) Abnormalities of the short arm of chromosome 9 with partial loss of material in hematological disorders. Leukemia 1: 541-548.
179. Peeters P, Raynaud SD, Cools J, et al. (1997) Fusion of Tel, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase Jak2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90: 2535-2540.
180. Lacronique V, Boureux A, Della Valle V, et al. (1997) A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278: 1309-1312.
181. Wasylyk B, Hahn SL, Giovane A. (1993) The Ets family of transcription
182. Ho JM-Y, Boattie BK, Squire JA, Frank DA, Barber DL. (1999) Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood 93: 4354-4364.
183. Schwaller J, Frantsve J, Aster J, et al. (1998) Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 17: 5321-5333.
184. Janssen JW, Ridge SA, Papadopoulos P, et al. (1995) The fusion of TEL and ABL in human acute lymphoblastic leukemia is a rare event. Br. J. Haematol. 90: 222-224.
185. Golub TR, Goga A, Barker G, et al. (1996) Oligomerization of the ABL tyrosine kinase by the ETS protein TEL in human leukemia. Mol. Cell. Biol. 16: 4107-4116.
186. Morris SW, Kirstein MN, Valentine MB, et al. (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263: 1281-1284.
187. Xiao S, Nalabolu SR, Aster JC, et al. (1998) FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat. Genet. 18: 84-87.
188. Golub TR, Barker GF, Lovett M, Gilliland DG. (1994) Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77: 307-316.
189. Abe A, Emi N, Tanimoto M, Terasaki H, Marunouchi T, Saito H. (1997) Fusion of the platelet-derived growth factor receptor β to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution. Blood 90: 4271-4277.
190. Ross T, Bernard O, Berger R, Gilliland DG. (1998) Fusion of the Huntington interacting protein 1 to platelet-derived growth factor β receptor (PDGFβR) in chronic myelomonocylic leukemia with t(5;7)(q33;q11.2). Blood 91: 4419-4426.
191. Vignais ML, Sadowski HB, Walling D, Rogers NC, Gilman M. (1996) Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol. Cell. Biol. 16: 1759-1769.
192. Valgeirsdottir S, Paukku K, Silvennoinen O, Heldin CH, Claesson-Welsh L. (1998) Activation of Stat5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation sites in PDGF beta-receptor juxtamembrane and kinase insert domains. Oncogene 16: 505-515.
193. Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG. (1996) The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myclomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc. Natl. Acad. Sci. U.S.A. 93: 14845-14850.
194. Joussert C, Carron C, Boureux A, et al. (1997) A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein. EMBO J. 16: 69-82.
195. Palmer AM, Mahajan S, Frank D, Gilliland DC, Carroll M. (1997) The TEL-PDGFβR transforming protein activates STAT1. Blood 90: 178a.
196. Garcia R, Jove R. (1998) Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J. Biomed. Sci. 5: 79-85.
197. Danial NN, Pernis A, Rothman PB. (1995) Jak-STAT signaling induced by the v-abl oncogene. Science 269: 1875-1877.
198. Danial NN, Losman JA, Lu T, et al. (1998) Direct interaction of Jak l and v-Abl is required for vAbl-induced activation of STATs and proliferation. Mol. Cel. Biol. 18: 6795-6804.
199. Yu C, Meyer DJ, Campbell GS, et al. (1995) Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269: 81-83.
200. Cao X, Tay A, Guy GR, Tan YH. (1996) Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol. Cell. Biol. 16: 1595-1603.
201. Chaturvedi P, Sharma S, Reddy EP. (1997) Abrogation of interleukin-3 dependence of myeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs. Mol. Cell. Biol. 17: 3295-3304.
202. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE Jr. (1998) Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol. 18: 2553-2558.
203. Caldenhoven E, van Dijk TB, Solari R, et al. (1996) STAT3beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J. Biol. Chem. 271: 13221-13227.
204. Turkson J, Bowman T, Garcia R, Caldenhuven E, de Groot RP, Jove R. (1998) Stat3 activation by src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol. 18: 2545-2552.
205. Campbell GS, Yu C-L, Jove R, Carter-Su C. (1997) Constitutive activation of Jak1 in Src-transformed cells. J. Biol. Chem. 272: 2591-2594.
206. Yu CL, Jove R, Burakoff SJ. (1997) Constitutive activation of the Janus kinase-STAT pathway in T lympboma overexpressing the Lek protein tyrosine kinase. J. Immunol. 159: 5206-5210.
207. Lund TC, Garcia R, Medveczky MM, Jove R, Medveczky PG. (1997) Activation of STAT transcription factors by herpesvirus Saimiri Tip-484 requires p56Ick. J. Viral. 71: 6677-6682.
208. Lund TC, Prator PC, Medveczky MM, Medveczky PG. (1999) The Lck binding domain of herpesvirus saimiri tip-484 constitutively activates Lck and STAT3 in T cells. J. Virol. 73: 1689-1694.
209. Zong C, Yan R, August A, Darnell JE Jr, Hanafusa H. (1996) Unique signal transduction of Eyk: constitutive stimulation of the JAK-STAT pathway by an oncogenic receptor-type tyrosine kinase. EMBO J. 15: 4515-4525.
210. Besser D, Bromberg JF, Darnell JE Jr, Hanafusa H. (1999) A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat3 and enhances cellular transformation. Mol. Cell. Biol. 19: 1401-1409.
211. Shimoda K, van Deursen J, Sangster MY, et al. (1996) Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 380: 630-633.
212. Takeda K, Tanaka T, Shi W, et al. (1996) Essential role of Stat6 in IL-4 signalling. Nature 380: 627-630.
213. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. (1996) Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp. Hematol. 24: 406-415.
214. Frank DA, Robertson M, Bonni A, Ritz J, Greenberg ME. (1995) IL-2 signaling involves the phosphorylation of novel Stat proteins. Proc. Natl. Acad. Sci. U.S.A. 92: 7779-7783.
215. Teglund S, McKay C, Schnetz E, et al. (1998) Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cylokine responses. Cell 93: 841-850.
216. Kaplan DH, Shankaran V, Dighe AS, et al. (1998) Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U.S.A. 95: 7556-7561.
217. Takeda K, Noguchi K, Shi W, et al. (1997) Targeted disruption of the mouse STAT3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. U.S.A. 94: 3801-3804.
218. Peppard JV, Loo P, Sills MA, Munster D, Pomponi SA, Wright AE. (1996) Characterization of an interleukin 6 cytokine family antagonist protein from a marine sponge, Callyspongia sp. J. Biol. Chem. 271: 7281-7284.
219. Savino R, Lahm A, Salvati AL, et al. (1994) Generation of interleukin-6 antagonists by molecular-modeling guided mutagenesis of residues important for gpl 30 activation. EMBO J. 13: 1357-1367.
220. Savino R, Ciapponi L, Lahm A, et al. (1994) Rational design of a receptor super-antagonist of human interleukin-6. EMBO J. 13: 5863-5870.
221. Kopf M, Baumann H, Freer G, et al. (1994) Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368: 339-342.
222. Klein B, Wijdenes J, Zhang XG, et al. (1991) Murine amtiinterleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78: 1198-1204.
223. Meydan N, Grunberger T, Dadi H, et al. (1996) Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379: 645-648.
224. Buchdunger E, Mett H, Trinks U, et al. (1995) 4,5-bis(4-fluoroanilino)phthalimide: a selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity. Clin. Cancer Res. 1: 813-821.
225. Buchdunger E, Zimmermann J, Melt H, et al. (1996) Inhibition of the ABL protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56: 100-104.
226. Mologni L, Cleris L, Marchesi E, et al. (1999) In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst. 91: 163-168.
227. Carroll M, Ohno-Jones S, Tamura S, et al. (1997) CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90: 4947-4952.
228. Traxler PM, Fyret P, Mett H, Buchdunger H, Meyer T, Lydon N. (1996) 4-(phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor tyrosine kinase. J. Med. Chem. 39: 2285-2292.
229. Druker BJ, Tamura S, Buchdunger E, et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2: 561-566.
230. Tomasson MH, Williams IR, Hasserjian R, et al. (1999) TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood 93: 1707-1714.
231. Frank DA, Mahajan S, Ritz J. (1999) Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat. Med. 5: 444-447.
232. Bromberg JF, Fan Z, Brown C, Mendelsohn J, Darnell JE Jr. (1998) Epidermal growth factor-induced growth inhibition requires Stal1 activation. Cell Growth Differ. 9: 505-512.
233. Kirkwood JM, Strawdermann MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. (1996) Interferon alla-2b adjuvant, therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14: 7-17.
234. Carson WE. (1998) Interferon-α-induced activation of signal transducer and activator of transcription proteins in malignant melanoma. Clin. Cancer Res. 4: 2219-2228.
235. Wong LH, Krauer KG, Hatzinisiriou I, et al. (1997) Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-lSGF3gamma. J. Biol. Chem. 272: 28779-28785.
236. Sun WH, Pabon C, Alsayed Y, et al. (1998) Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood 91: 570-576.
237. Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE Jr. (1996) Transcriptionally active Stat1 is required for the antiproliferative effects of both Interferon alpha and interferon gamma. Proc. Natl. Acad. Sci. U.S.A. 93: 7673-7678.
238. Warrell RP Jr, Frankel SR, Miller WJJ, et al. (1991) Differentiation therapy of acute promyelocytic leukemia with triretinoin (all-trans retinoic acid). N. Engl. J. Med. 324: 1385-1391.
239. Gianni M, Terao M, Fortino I, et al. (1997) Stat1 is induced and activated by all-trans retinoic acid in acute promyelocylic leukemia cells. Blood 89: 1001-1012.
240. Weihua X, Kolla V, Kalvakolanu DV. (1997) Modulation of interferon action by retinoids. Induction of murine STAT1 gene expression by retinoic acid. J. Biol. Chem. 272: 9742-9748.
241. Kalvakolanu DV, Sen GC. (1993) Differentiation-dependent activation of interferon-stimulated gene factors and transcription factor NFkappa B in mouse embryonal carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 90: 3167-3171.
242. Kolla V, Lindner DJ, Weihua X, Borden EC, Kalvakolanu DV. (1996) Modulation of interferon (IFN)-inducible gene expression by retinoic acid, Up-regulation of Stat1 protein in IFN-unresponsive cells. J. Biol. Chem. 271: 10508-10514.
243. Matikainen S, Ronni T, Lehtonen A, et al. (1997) Retinoic acid induces signal transducer and activator of transcription (STAT) 1, STAT2, and p48 expression in myeloid leukemia cells and enhances their responsiveness to interferons. Cell Growth Differ. 8: 687-698.
244. Aragane Y, Kulms TJ, Luger TA, Schwarz T. (1997) Down-regulation of interferon γ-activated STAT1 by UV light. Proc. Natl. Acad. Sci. U.S.A. 94: 11490-11495.
245. Look DC, Roswit WT, Frick AG, et al. (1998) Direct suppression of Stal1 function during adenoviral infection. Immunity 9: 871-880.